Vaccines for preventing tick-borne encephalitis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Demicheli, Vittorio ^a   Debalini, Maria Grazia ^b   Rivetti, Alessandro ^c  

^a Health Councillorship Servizio Regionale di Riferimento Per l'Epidemiologia   (Italy)

^b ASL 20   (Italy)

^c Servizio Regionale di Riferimento Per l'Epidemiologia   (Italy)

Author keywords

Adult; Child; Encephalitis, tick borne immunology; *prevention control; Humans; Infant; Randomized controlled trials as topic; Viral vaccines immunology; *therapeutic use

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED VACCINE; INSECT REPELLENT; LIVE VACCINE; PLACEBO; THIOMERSAL; TICK BORNE ENCEPHALITIS VACCINE;

ABDOMINAL PAIN; ADVERSE OUTCOME; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ASTHENIA; BIRTH DEFECT; BLOOD SAMPLING; BODY TEMPERATURE; CEREBROSPINAL FLUID CULTURE; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEATH; DISABILITY; DISEASE CARRIER; DISEASE COURSE; DISEASE TRANSMISSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EMBASE; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEVER; FOLLOW UP; FORMICATION; HEADACHE; HEARING LOSS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INCUBATION TIME; INFECTION PREVENTION; INFORMATION RETRIEVAL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INOCULATION; INSOMNIA; IRRITABILITY; MALAISE; MEDLINE; MENINGITIS; MENINGOENCEPHALITIS; MYALGIA; MYELITIS; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREVALENCE; RADICULITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEROCONVERSION; SERODIAGNOSIS; SEROLOGY; SIDE EFFECT; SWELLING; SYSTEMATIC REVIEW; TICK BORNE ENCEPHALITIS; TREATMENT CONTRAINDICATION; TREMOR; VIREMIA; VOMITING; WEAKNESS;

EID: 70349098850     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000977.pub2     Document Type: Review

References (59)

1. Bock H, Klockmann U, Jüngst C, Schindel-Künzel F, Theobald K, Zerban R. A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study. Vaccine 1990;8(1):22-24 (Pubitemid 20112878)
2. Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children. Vaccine 2003;21(25-26):3575-3583 (Pubitemid 37338181)
3. Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children. Vaccine 2003;21(25-26):3575-3583 (Pubitemid 37338181)
4. Ehrlich HJ, Pavlova BG, Fritsch S, Poellabauer EM, Loew-Baselli A, Obermann-Slupetzky O, et al.Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 2003;22(2):217-223 (Pubitemid 37412265)
5. Girgsdies OE, Rosenkranz G. Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study. Vaccine 1996;14(15):1421-1428 (Pubitemid 27008257)
6. Harabacz I, Bock H, Jüngst C, Klockmann U, Praus M, Weber R. A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens. Vaccine 1992;10(3):145-150
7. Immuno AG. A double-blind study designed to investigate the immunogenicity of three TBE vaccines. 1996. Unpublished.
8. Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, et al. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine 2006;24(24):5256-5263 (Pubitemid 43833473)
9. Pavlova LI, Gorbunov MA, Vorob'eva MS, Karavanov AS, Grachev VP, Ladyshenskaia IP, et al.A cultured concentrated inactivated vaccine against tick-borne encephalitis studied during the immunization of children and adolescents [Izuchenie kul'tural'noi kontsentrirovannoi inaktivirovannoi vaktsiny protiv kleshchevogo entsefalita pri immunizatsii detei i podrostkov]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1999, (6):50-53
10. Schoendorf I, Ternak G, Oroszlan G, Nicolay U, Banzhoff A, Zent O. Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Human Vaccines 2007;3(2):42-47 (Pubitemid 46493604)
11. Schöndorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tickborne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 2007;25(8):1470-1475 (Pubitemid 46091819)
12. Baumhackl U, Franta C, Retzl J, Salomonowitz E, Eder G. A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 2003;21 Suppl 1:56-61. (Pubitemid 36288526)
13. Craig SC, Pittman PR, Lewis TE, Rossi CA, Henchal EA, Kuschner RA, et al.An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia. American Journal of Tropical Medicine and Hygiene 1999;61(6):874-878
14. Dengler TJ, Zimmermann R, Meyer J, Sack FU, Girgsdies O, Kübler WE. Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 1999;17(7-8):867-874 (Pubitemid 29074741)
15. von Hedenström M, Heberle U, Theobald K. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events. Vaccine 1995;13(8):759-762
16. Leonova GN, Ternovoi VA, Pavlenko EV, Maistrovskaya OS, Protopopova EV, Loktev VB. Evaluation of vaccine Encepur Adult for induction of human neutralizing antibodies against recent Far Eastern subtype strains of tick-borne encephalitis virus. Vaccine 2007;25 (5):895-901.
17. Mamoli B, Pateistky K. Placebo controlled EEG double blind study with the further purified TBE-vaccine. In: Kunz C editor(s). Tickborne encephalitis. Vienna: Facultas-Verlag, 1981:208-216
18. Panasiuk B, Prokopowicz D, Panasiuk A. Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection 2003;31(1):45-46 (Pubitemid 36183084)
19. Rosenkranz G. Can we reduce the dose of a vaccine?. Controlled Clinical Trials 1997;18(1):43-53.
20. Schöndorf I, Schönfeld C ,Nicolay U, Zent O, Banzhoff A. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule. International Journal of Medical Microbiology 2006;296 Suppl 40: 208-212 (Pubitemid 43668609)
21. Vene S, Haglund M, Lundkvist A, Lindquist L, Forsgren M. Study of the serological response after vaccination against tick-borne encephalitis in Sweden. Vaccine 2007;25(2):366-372 (Pubitemid 44873144)
22. Zent O, Jilg W, Plentz A, Schwarz TF, Frühwein N, Kuhr HB, Banzhoff A, et al.Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine 2003;21(32): 4655-4660 (Pubitemid 37329859)
23. Zoulek G, Roggendorf M, Deinhardt F, Kunz C. Different immune responses after intradermal and intramuscular administration of vaccine against tick-borne encephalitis virus. Journal of Medical Virology 1986;19(1):55-61. (Pubitemid 16142972)
24. Popov OV, Sumarokov AA, Shkol'nik RIa, El'bert LB, Vorob'eva MS. A study of the reactogenic and antigenic potency of dried chromatographic purified concentrated inactivated dried vaccine against tickborne encephalitis. Zhurnal Mikrobiologii Epidemiologii, i Immunobiologii 1985, (6):34-39
25. Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, et al.Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 2008;26(7):882-890
26. NCT00118924. Phase 1 study of the safety and immunogenicity of tick-borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a live attenuated vaccine for tick-borne encephalitis. clinicaltrials. gov/show/NCT00118924 (accessed 28 October 2008).
27. NCT00161746. Multicentre randomized double-blind Phase II/III study on the safety and immunogenicity of three vaccinations With TICOVAC in two dosages in healthy children aged between six months and three years. clinicaltrials.gov/show/NCT00161746 (accessed 28 October 2008).
28. NCT00161772. Double-blind, randomized, multicenter dose-finding study to investigate the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 1 to 6 years. clinicaltrials.gov/show/NCT00161772 (accessed 28 October 2008).
29. NCT00161785. Investigation of the seropersistence of TBE antibodies and the booster response to FSME-IMMUN 0.5 ml in adults aged 18-67 years. clinicaltrials.gov/show/NCT00161785 (accessed 28 October 2008).
30. NCT00161798. Double-blind, randomized, multicenter dose-finding study to investigate the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16 years. clinicaltrials.gov/show/ NCT00161798 (accessed 28 October 2008).
31. NCT00161824. Single-blind, randomized, multicenter comparison of FSME IMMUN NEW and ENCEPUR: safety and tolerability of two vaccinations in healthy volunteers aged 16 to 65 years. clinicaltrials. gov/show/NCT00161824 (accessed 28 October 2008).
32. NCT00161850. Follow-up study to investigate the safety and immunogenicity of a third vaccination with three different antigen concentrations of FSME IMMUN NEW in children aged 1 to 6 years. clinicaltrials.gov/show/NCT00161850 (accessed 28 October 2008).
33. NCT00161889. Follow-up study to investigate the safety and immunogenicity of a third vaccination with three different antigen concentrations of FSME IMMUN NEW in children aged 6 to 16 years. clinicaltrials.gov/show/NCT00161889 (accessed 28 October 2008).
34. NCT00311441. A Phase IV, randomized, controlled, single-blind, multi-center study in children to evaluate the safety, tolerability and immunogenicity of two TBE vaccines administered according to two different schedules. clinicaltrials.gov/ct2/show/record/NCT00311441 (accessed 28 October 2008).
35. NCT00311493. A Phase IV, randomized, open-label, multi-center study in adults: evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in Study V48P2E1, 5 years after first booster immunization and evaluation of booster kinetics in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer), 5 years after first booster immunization. clinicaltrials.gov/show/ NCT00311493 (accessed 28 October 2008).
36. Asokliene L. Tickborne encephalitis in Lithuania.. Eurosurveillance Weekly Release 2004;8(26).
37. Barret PN, Dorner F, Plotkin SA. Tick-borne encephalitis vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. London: Saunders, 1999:773.
38. Barrett PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine 2003;21 Suppl 1:41-49
39. Beran J. Tickborne encephalitis in the Czech Republic. Eurosurveillance Weekly Release 2004;8(26).
40. Clement J, Vandevelde C, Kunz C, Gould E. "New" flaviviruses (FV) circulating in S. Germany (abstract). Symposium on modern approaches to flavivirus vaccines. Vienna, Austria, 1996.
41. Council of Europe. European Pharmacopoeia 1999 Supplement. 3rd Edition. Strasbourg: European Pharmacopoeia Commission, 1999.
42. Donoso Mantke O, Schadler R, Niedrig M. A survey on cases of tickborne encephalitis in European countries. Eurosurveillance 2008;13 (17):18848.
43. Ecker M, Allison SL, Meixner T, Heinz FX. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. Journal of General Virology 1999;80 Pt 1:179-185 (Pubitemid 29041696)
44. Haglund M, Gunther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine 2003;21 Suppl 1: 11-18 (Pubitemid 36292201)
45. Hayasaka D, Ivanov L, Leonova GN, Goto A, Yoshii K, Mizutani T, et al.Distribution and characterization of tick-borne encephalitis viruses from Siberia and far-eastern Asia. Journal of General Virology 2001;82 Pt 6:1319-1328 (Pubitemid 32519761)
46. Holzmann H, Kundi M, Stiasny K, Clement J, McKenna P, Kunz C, et al.Correlation between ELISA, haemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. Journal of Medical Virology 1996;48(1):102-107 (Pubitemid 26144865)
47. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine 2003; 21 Suppl 1:36-40.
48. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323 (7303):42-46 (Pubitemid 32682008)
49. Kaiser R. Clinical description. Tick borne encephalitis (TBE, FSME):Monograph; www.iswtbe. info/upload/medialibrary/Monograph-TBE.pdf March 2007 (accessed 11 September 2008):21-28
50. Kunz C. Tick-borne encephalitis in Europe. Acta Leidensia 1992;60 (2):1-14.
51. Kunze U, Asokliene L, Busse A, Chmelik V, Heinz FX, Hingst V, et al.Tick borne encephalitis in childhood: conference report and consensus of the International Scientific Working Group on tickborne encephalitis (ISW-TBE). Vaccine 2004;26(6):729-731 (Pubitemid 39473169)
52. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
53. Lucenko I, Jansone I, Velicko I, Pujate E. Tickborne encephalitis in Latvia. Eurosurveillance Weekly Release 2004;8(26).
54. Rendi-Wagner P. Risk and prevention of tick-borne encephalitis in travelers. Journal of Travel Medicine 2004;11(5):307-312 (Pubitemid 39482177)
55. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
56. Strauss R, Samuelsson S, Nohynek H, Hellenbrand W, Steffens I, Molnár Zs, et al.Tickborne encephalitis in Europe: basic information, country by country. Eurosurveillance Weekly Release 2004;8(29).
57. Süss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine 2003;21 Suppl 1:19-35.
58. Zlobin VI. Tick-borne encephalitis in the Russian Federation: state-of-the-art and prevention policy. Voprosy Virusologii 2005;50(3):26-32.
59. Demicheli V, Graves P, Pratt M, Jefferson T. Vaccines for preventing tick-borne encephalitis. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000977]